Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
308
Total raised
£4.1B
disclosed amounts
This month
£27.8M
raised so far
The financing round was led by aMoon and will support clinical trials and research pipelines.
"Since the inception of MiNA Therapeutics, we have been focused on advancing the Company by validating our innovative therapeutic approach in patients and establishing strategic collaborations with leading academic institutions and industry partners,"
The funding round was led by Mercia and will support the firm in progressing its multi-cancer diagnostic programmes.
"Worldwide, 26,000 people die from cancer each day. Early detection is critical for effective treatment, but many cancers go undetected for too long. This funding is another significant step forward for ClinSpec Dx in our mission to detect cancer earlier and help to increase patient survival and quality of life."
Maven Capital Partners co-led the £3.4m round to support the firm in scaling its operations overseas, notably in the US market.
"Gen inCode represents a fantastic opportunity for Maven to support a truly innovative business which is utilising AI and bioinformatics in order to enable medical practitioners to make more proactive, precise and impactful decisions on how they treat their patients. The precision medicine market is an exciting space and webelieve Gen inCode is well positioned to grow, leveraging its advanced genomic technology and the valuable IP it has amassed to date. We look forward to working with the senior management team to fulfil the company’s potential."
The seed follow-on round was led by the Government Future Fund with matching contributions from Saker Capital and North East Innovation Fund.
"Magnitude has demonstrated high agility and resilience during the pandemic and has proven to be a fast growing business in trying times. Our investment will consolidate its position as a rising contract research services provider to the UK’s biotech sector."
The company has received a cash grant from the UK government to adapt its cell preservation gel for coronavirus testing samples.
"In June, 30,000 COVID-19 tests in the UK were recorded as invalid. One reason behind this higher than expected figure was that scientists were unable to preserve the integrity of swab samples for longer than 72 hours, leading to the government committing to having swab test results completed within 24 hours. However, when testing tens of thousands of swab tests, backlogs are inevitably going to occur, meaning swab tests need to be stored so that they can be tested later. What our solution provides is an ability to store samples for up to two weeks meaning test samples do not become redundant after 72 hours, thereby providing scientists more time to handle large volumes of swab tests."
